financetom
Business
financetom
/
Business
/
Alpha Teknova, Pluristyx Partner to Produce, Distribute PluriFreeze for Cell Therapies
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alpha Teknova, Pluristyx Partner to Produce, Distribute PluriFreeze for Cell Therapies
Mar 12, 2025 1:32 AM

04:12 AM EDT, 03/12/2025 (MT Newswires) -- Alpha Teknova ( TKNO ) and Pluristyx said late Tuesday they are collaborating to produce and commercialize the latter's PluriFreeze product line, a cryopreservative and cell wash media system for allogeneic cell therapies.

Under the partnership, the companies said Teknova will be the exclusive manufacturer and distributor of PluriFreeze in the US and Canada.

The PluriFreeze system, which is entirely synthetic and animal-origin-free, includes a protective wash and a freezing medium designed to support cell therapy development, the companies said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Keyera Sanctions KAPS Zone 4 Pipeline Extension
Keyera Sanctions KAPS Zone 4 Pipeline Extension
Jun 9, 2025
07:52 AM EDT, 06/09/2025 (MT Newswires) -- Keyera ( KEYUF ) reported Monday the formal sanctioning of the KAPS Zone 4 extension of its existing KAPS pipeline, strengthening the company's connectivity to the liquids-rich Montney regions of northeast British Columbia and northwest Alberta. The company expects the 85-kilometer extension to cost $220 million, which includes investments in additional pumping capacity...
Axsome Therapeutics Receives FDA's Refuse-to-File Letter for AXS-14 New Drug Application
Axsome Therapeutics Receives FDA's Refuse-to-File Letter for AXS-14 New Drug Application
Jun 9, 2025
07:59 AM EDT, 06/09/2025 (MT Newswires) -- Axsome Therapeutics ( AXSM ) said Monday that it received a refuse to file letter from the US Food and Drug Administration for its new drug application for AXS-14 in fibromyalgia. According to Axsome, the regulator found that its NDA was not sufficient for a substantive review, as the second of two placebo-controlled...
Sherritt International Chairman Richard Lapthorne Retires
Sherritt International Chairman Richard Lapthorne Retires
Jun 9, 2025
07:53 AM EDT, 06/09/2025 (MT Newswires) -- Sherritt International ( SHERF ) on Monday said Sir Richard Lapthorne retired as board chair due to personal reasons. Sir Richard chaired the board since June 2019. Sherritt ( SHERF ) last week reported that Institutional Shareholder Services recommended that shareholders vote for all resolutions and director nominees ahead of the annual and...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved